Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Resveratrol, a polyphenolic compound found in grapes, berries, and peanuts, has been investigated for its potential cardiovascular benefits, including in the context of arteriosclerosis (atherosclerosis). Most available evidence comes from preclinical studies and a limited number of small-scale human trials. In animal models and in vitro experiments, resveratrol (and its conjugates, such as glucuronides and sulfates, which are more common in plasma after ingestion) has demonstrated anti-inflammatory, antioxidant, and vasodilatory properties. These actions could theoretically reduce the progression of arterial plaque and improve endothelial function, mechanisms underlying arteriosclerosis.

However, clinical evidence in humans remains limited and inconsistent. Some small trials have shown modest improvements in markers of vascular health (e.g., endothelial function, LDL oxidation), but large, well-controlled studies demonstrating a clear reduction in arteriosclerosis incidence or progression are lacking. Reviews and meta-analyses generally conclude that while there is biological plausibility and some promising signals, the clinical significance is uncertain due to issues of bioavailability, dosage, and variability in study results. Thus, resveratrol conjugates are sometimes used as a supplement with the intention of supporting cardiovascular health, but the level of scientific validation for their use in treating arteriosclerosis is currently low to moderate.

More about Resveratrol conjugates (mixed)
More about Arteriosclerosis

Other ingredients used for Arteriosclerosis

Other health conditions supported by Resveratrol conjugates (mixed)

Products containing Resveratrol conjugates (mixed)